Rash News and Research

RSS

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

13 Sep 2011

U-M offers transplantation for patients with bile duct cancer

Robert "Buzz" Gehle thought the itchy rash he was experiencing was a recurrence of an earlier case of shingles. But when his doctor saw he was also jaundiced, he immediately knew there was a problem with Gehle's liver.

30 Aug 2011

Firazyr receives FDA approval for treatment of HAE acute attacks

The U.S. Food and Drug Administration today approved Firazyr (icatibant) Injection for the treatment of acute attacks of a rare condition called hereditary angioedema (HAE) in people ages 18 years and older.

26 Aug 2011

Measles exposure in Philadelphia and Lancaster counties

The Pennsylvania Department of Health and the Philadelphia Department of Public Health are advising the public of exposure to a case of measles in Lancaster and Philadelphia counties.

24 Aug 2011

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated today announced that Health Canada has approved INCIVEK tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

23 Aug 2011

FDA approves Zelboraf (vemurafenib) for advanced skin cancer

A new drug was approved for advanced skin cancer this Wednesday by U.S. regulators, offering the first new treatment for melanoma in 13 years.

18 Aug 2011

Zelboraf receives FDA approval for treatment of metastatic melanoma

The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

17 Aug 2011

First anti-venom for scorpion bites approved by FDA

The U.S. Food and Drug Administration (FDA) has approved a Mexican-made drug that is the first specific treatment for stings by the most common type of scorpion in the United States. The new preparation called Anascorp is found to have few allergic reactions and was approved after a series of clinical trials by the University of Arizona.

5 Aug 2011

New legislation allows physicians in Texas to treat chronic Lyme disease

Summertime, when kids and grown-ups abandon the confines of the indoors and head outside to camp, hike, fish and commune with nature -- and all of her friends. Flies, mosquitoes and ticks are just a few of the critters that go along with summer outdoors, and we all do our best to avoid the biting and stinging insects, but what happens if you are accosted by a tick? What are the myths behind Lyme disease and other tick-borne diseases in Texas?.

5 Aug 2011

Tips to minimize risk of bug bites and related illnesses

While the image of a bug crawling on your arm or a creepy crawler snuggling up in your bed is enough to make you flinch, most bug bites are harmless and disappear on their own in a matter of days. Other insects, however, can spread disease and cause severe reactions that require medical attention.

4 Aug 2011

Instituto Bioclon receives FDA approval for Anascorp to treat Centruroides scorpion sting

The U.S. Food and Drug Administration today approved Anascorp, the first specific treatment for a scorpion sting by Centruroides scorpions in the United States.

4 Aug 2011

Fluoride supplements neither safe or effective

Sodium fluoride supplements "have not been found by FDA to be safe or effective," according to the U.S. National Library of Medicine's website, reports the New York State Coalition Opposed to Fluoridation, Inc..

25 Jul 2011

Bristol-Myers Squibb announces results of BMS-708163 Phase II study on Alzheimer's

Bristol-Myers Squibb Company today announced the results of a Phase II study evaluating the safety and tolerability of the investigational gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate Alzheimer's disease.

21 Jul 2011

Promising results from phase I study of Genentech's GDC-0941 for advanced breast cancer

A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology.

21 Jul 2011

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.

20 Jul 2011

Measles epidemic grips Kenya and Ethiopia

The UNICEF announced Friday that children in Kenya and Ethiopia are at risk of a measles epidemic. Ethiopia has had more than 17,584 cases of measles in 2011, with 114 deaths. The WHO urges measles vaccination of young children to combat the situation.

18 Jul 2011

Zocor, Crestor drugs may cause serious muscle and kidney problems

Crestor and Zocor are widely-used prescription strength drugs designed to lower "bad cholesterol". Both drugs are classified as "statins", medicine which lowers blood cholesterol levels by inhibiting HMG-CoA reductase.

16 Jul 2011

Berks County's Department of Health advises public about possible measles exposure

The state Department of Health is advising the public of a possible case of measles exposure in Morgantown, Berks County.

15 Jul 2011

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Sanofi and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif in patients with relapsing-remitting multiple sclerosis.

11 Jul 2011

PEP intervention increases breast cancer awareness

Educating women about breast cancer increases their knowledge about the disease should they develop a symptom - and could help increase survival from breast cancer, new research today shows.

29 Jun 2011